Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 2, 2017
Issued Date -
N/A
app pub date -
May 21, 2014
filing date -
May 21, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully